CALIWAY BIOPHARMACEUTICALS CO L
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for … Read more
CALIWAY BIOPHARMACEUTICALS CO L (6919) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.007x
Based on the latest financial reports, CALIWAY BIOPHARMACEUTICALS CO L (6919) has a cash flow conversion efficiency ratio of -0.007x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-68.22 Million) by net assets (NT$9.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CALIWAY BIOPHARMACEUTICALS CO L - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how CALIWAY BIOPHARMACEUTICALS CO L's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CALIWAY BIOPHARMACEUTICALS CO L Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CALIWAY BIOPHARMACEUTICALS CO L ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aneka Tambang (Persero) TBK (PT)
AU:ATM
|
0.051x |
|
Isupetasys
KO:007660
|
0.097x |
|
Life Time Group Holdings Inc
NYSE:LTH
|
0.084x |
|
A2 Milk Company Ltd
F:14L
|
0.040x |
|
Technip Energies N.V
PINK:THNPF
|
0.140x |
|
Thyssenkrupp AG O.N.
PINK:TYEKF
|
0.156x |
|
Bharat Heavy Electricals Limited
NSE:BHEL
|
-0.048x |
|
Yuhan Corp.
KO:000100
|
0.035x |
Annual Cash Flow Conversion Efficiency for CALIWAY BIOPHARMACEUTICALS CO L (2021–2024)
The table below shows the annual cash flow conversion efficiency of CALIWAY BIOPHARMACEUTICALS CO L from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$9.70 Billion | NT$-522.31 Million | -0.054x | +52.47% |
| 2023-12-31 | NT$3.74 Billion | NT$-423.94 Million | -0.113x | +45.65% |
| 2022-12-31 | NT$1.16 Billion | NT$-242.76 Million | -0.209x | -21.43% |
| 2021-12-31 | NT$644.66 Million | NT$-110.69 Million | -0.172x | -- |